Nektar will release 24-week off-treatment data for rezpegaldesleukin in alopecia areata, testing durability after dosing ends in the Phase...

JST-018 orthopoxvirus antibody enters phase 1 trial under $123.9M defense contract with Just-Evotec Biologics for warfighter protection.

BridgeBio shifts BBO-8520 focus to KRAS combinations in second-line NSCLC, building on a 63% response rate from monotherapy.

Novartis triggers $50M milestone payment as MRT-6160 enters Phase 2 for Sjögren's disease, advancing VAV1 degrader development.

Mosliciguat advances to Phase 3 PHrontier Trial after PHocus Study shows 20% pulmonary vascular resistance reduction in PH-ILD patients.

Six AI models picked the same "random" number. Clinical ops leaders are finally asking what that reveals about every...

FDA's August 2026 warning letter to Fresenius Kabi's Ogden, Utah plant exposes how sponsor oversight of CMOs fails long...

A landmark Nature Medicine RCT found AI improved clinician decisions but not patient outcomes, exposing the fatal flaw in...

Clinical trial sites should establish data infrastructure before deploying AI tools, according to industry experts and recent guidance on...

Ascendis will present sentinel cohort data from the reACHin Trial of navepegritide infant trial at ESPE 2026, extending the...